ライフサイエンスコーパス: radiochemical

1 incorporation of the alpha-particle-emitting radiochemical ((210)Po-citrate) and 2 anticancer drugs (

2 roperties regarding clinical performance and radiochemical accessibility.

3 Radiochemical analyses were performed on the following r

4 Radiochemical analysis demonstrated that the postpurific

5 F-GLN and (18)F-(2S,4R)4F-GLU with confirmed radiochemical and enantiomeric purity.

6 The produced (132/135)La(3+) has a radiochemical and radionuclidic purity amenable for (132

7 ertechnetate 99mTc was assayed for chemical, radiochemical, and radionuclidic purity.

8 es such compounds interesting candidates for radiochemical applications.

9 thelial cells, studies of drug release using radiochemical approaches showed that the presence of 10v

10 inefficient and/or poorly defined multistep radiochemical approaches.

11 luorescent assay combines the sensitivity of radiochemical assays with the simplicity of nonradiochem

12 In characterizing AdPLA, we employed radiochemical assays with TLC analysis of the enzyme act

13 ntages over the more traditional assay using radiochemical ATP and column chromatography.

14 diosynthesis of 5'-[(18) F]FDA, with overall radiochemical conversion (RCC) more than 3-fold higher t

15 nmol(-1) Reaction optimization improved the radiochemical conversion of (89)Zr-DFO-azepin-onartuzuma

16 abeled isoquinolines resulting in up to 92 % radiochemical conversion.

17 beling of a variety of carboxylic acids with radiochemical conversions up to 50 %, representing a tar

18 erformance liquid chromatography (HPLC) with radiochemical detection to determine relative levels of

19 ning pharmaceuticals were prepared with high radiochemical efficiency.

20 Most Ac chemistry is inferred from radiochemical experiments carried out on microscopic sca

21 A panel of radiochemicals has enabled in vivo positron emission tom

22 ypoxia could be useful tools that complement radiochemical imaging and immunohistochemical staining m

23 se findings were supported by the results of radiochemical in situ hybridization histology and quanti

24 Previous radiochemical incorporation experiments and bioinformati

25 results supersede proposals based on earlier radiochemical incorporation experiments.

26 for the low energy cyclotron production and radiochemical isolation of no-carrier-added (132/135)La(

27 ack of chemically diverse precursors, and of radiochemical methods allowing (18)F-incorporation in hi

28 f PET has led to an increased demand for new radiochemical methods to synthesize highly specific mole

29 n and counting techniques, radioisotopes and radiochemical methods uniquely contribute to the health

30 h ruggedness tests, the application field of radiochemical methods used was extended successfully to

31 y sensitive and comparable with detection by radiochemical methods.

32 orobenzaldehyde using an aniline-accelerated radiochemical oximation reaction.

33 -SFB was efficiently prepared using a 3-step radiochemical pathway.

34 The radiochemical procedure was validated by its application

35 this review we explore the coordination and radiochemical properties of yttrium, and its role in dru

36 automatic synthesizer with good chemical and radiochemical purities and enantiomeric excess values.

37 elds of 61% (decay-corrected) or greater and radiochemical purities greater than 99%.

38 Both kits achieved the radiochemical purities of > 95%.

39 The chemical and radiochemical purities of (18)F-F13714 were greater than

40 orT in radiochemical yields of about 30% and radiochemical purities of greater than 99%.

41 corrected yields ranging from 60% to 70% and radiochemical purities of more than 99%.

42 Chemical and radiochemical purities of TP3939 were 96.8% and 98% +/-

43 activities (45-95 GBq/mumol), and excellent radiochemical purities.

44 cal purity suitable for biologic evaluation (radiochemical purity > 95%, decay-corrected radiochemica

45 activities ranging from 52 to 65 GBq/mumol (radiochemical purity > 99%).

46 We synthesized [(14)C]TETS (14 mCi/mmol, radiochemical purity >99%) by reacting sulfamide with H(

47 a 51% +/- 19% radiochemical yield with high radiochemical purity (>/=98%).

48 ribed in this study could be labeled to high radiochemical purity (>95%, 2.2-4.5 MBq/nmol).

49 .70 GBq, 66 +/- 19 mCi, 5 +/- 1%), excellent radiochemical purity (>98%) and high molar activity (76

50 y corrected), and has excellent chemical and radiochemical purity (>98%) as well as high molar activi

51 des, can be synthesized in good chemical and radiochemical purity (>98%), satisfactory radiochemical

52 ochemical yield of 2 +/- 0.6% with excellent radiochemical purity (>99%) and showed complete stabilit

53 iochemical yield (36% +/- 7% [mean +/- SD]), radiochemical purity (>99%), and mean molar activity (1,

54 u]-NPs of uniform shape and size with a high radiochemical purity (>99%), specific activity of 2.2 mC

55 radiochemical yield (24-52% n = 8) and high radiochemical purity (>99%).

56 chemical yield, respectively, with excellent radiochemical purity (>99%).

57 s developed, providing a radiotracer of high radiochemical purity (>99%).

58 fluorination, affording a product with >99% radiochemical purity (RCP) and specific activity (SA) of

59 )Ga-NeoBOMB1 (50 mug) was prepared with high radiochemical purity (yield > 97%).

60 efficient, resulting in ADCs with 96% to 98% radiochemical purity after size-exclusion chromatography

61 The radiochemical purity after solid-phase extraction purifi

62 A-hu14.18K322A was achieved at more than 95% radiochemical purity and a specific activity of 127-370

63 -fluoromaltotriose was synthesized with high radiochemical purity and evaluated in several clinically

64 ng procedure yielded a compound with 95%-99% radiochemical purity and good in vitro stability.

65 (11)C-LY2459989 was synthesized in high radiochemical purity and good specific activity.

66 vides radiolabeled peptides with high (>98%) radiochemical purity and greater than 80% radiochemical

67 172176 was synthesized with greater than 99% radiochemical purity and high molar activity.

68 05270430 was synthesized in greater than 98% radiochemical purity and high specific activity.

69 We were able to produce (68)Ga-FOL with high radiochemical purity and moderate molar activity.

70 18)F to afford (18)F-OF-NB1 in more than 95% radiochemical purity and molar activities of 192 +/- 33

71 The radiochemical purity and protein integrity were more tha

72 Chemical and radiochemical purity and serum stability were determined

73 ing antibody trastuzumab and labeled in high radiochemical purity and specific activity with the radi

74 The radiochemical purity and stability of the compound was a

75 Radiochemical purity and sterility were examined.

76 )(3)(ASMA) preparations had greater than 99% radiochemical purity and were stable in phosphate-buffer

77 btained in the (18)F-radiolabeled form, with radiochemical purity and yield suitable for preliminary

78 /D3 receptor by carbonylation with excellent radiochemical purity and yield.

79 ]Cu-NOTA-HsTX1[R14A] was synthesised in high radiochemical purity and yield.

80 ined in 25 min (n = 5) with greater than 99% radiochemical purity at high specific activity (>111 GBq

81 2 h after injection and was dependent on the radiochemical purity at the time of injection.

82 tively stable in 25 mM NH(4)OAc, pH 6.9, and radiochemical purity decreased from 98.5% at purificatio

83 The radiochemical purity exceeded 99% in all syntheses.

84 up to 1.5 GBq of tracer were produced with a radiochemical purity greater than 95% in less than 30 mi

85 cluding work-up took about 20-30 min, with a radiochemical purity greater than 95% without the need f

86 ne, patient batches (>200 applications) with radiochemical purity greater than 98% and specific activ

87 f 8.0 x 10(7) MBq/mmol (2,166 Ci/mmol) and a radiochemical purity greater than 98%.

88 y in the range of 888-3,774 GBq/mumol, and a radiochemical purity greater than 99% using an automatic

89 DFO-AC-10 with a radiochemical yield of 80%, radiochemical purity greater than 99%, and specific acti

90 (89)Zr-DFO-daratumumab was synthesized with radiochemical purity greater than 99%.

91 of (11)C-cholylsarcosine was produced with a radiochemical purity greater than 99%.

92 l radiochemical uncorrected yield of 15% and radiochemical purity higher than 98%.

93 uncorrected for decay) and greater than 98% radiochemical purity in a synthesis time of 10 min.

94 ecay-corrected) based on [(11)C]CO(2) with a radiochemical purity of >98% and molar activity of 98 +/

95 The radiochemical purity of (64)Cu-TP3805 was 97% +/- 2%, an

96 ith a radiochemical yield of 15.1% +/- 5.6%, radiochemical purity of 96.7% +/- 2.0%, and specific act

97 overall recovery yield of 91 +/- 3%, average radiochemical purity of 99.9%, and production yields tha

98 rected radiochemical yield (RCY) of 24.8%, a radiochemical purity of approximately 90%, and a molar a

99 The radiochemical purity of both (68)Ga-DOTATOC and (68)Ga-P

100 MSB0010853 with (89)Zr was performed with a radiochemical purity of greater than 95%.

101 d from 40 to 336 GBq/mumol, and an excellent radiochemical purity of greater than 99% was achieved.

102 isolated RCYs of 41.2% +/- 10.6% (n = 3) and radiochemical purity of more than 90%.

103 2 and (18)F-AlF-RESCA-IL2 were produced with radiochemical purity of more than 95% and radiochemical

104 specific activity of 52-224 MBq/nmol, and a radiochemical purity of more than 97% (90 min from end o

105 Anti-CD56 mAb was radiolabeled, achieving a radiochemical purity of more than 97% and a specific act

106 zumab with an isolated RCY of more than 97%, radiochemical purity of more than 97% and molar activity

107 activity of approximately 20 GBq/mumol and a radiochemical purity of more than 98% for (64)Cu-NOTA-AE

108 ed with a 15% radioactivity yield and a high radiochemical purity of more than 99%.

109 lated in an overall yield of 68% +/- 5% with radiochemical purity of more than 99.5%.

110 The radiochemical purity of Na(2)[(99m)Tc(CO)(3)(NTA)] was g

111 mCi/mL), which is sufficient for analysis of radiochemical purity of radiopharmaceuticals.

112 The radiochemical purity of the (18)F-DEG-VS-NT was greater

113 Radiochemical purity of the isolated (211)At was assesse

114 ed with a (99m)Tc-tricarbonyl precursor, and radiochemical purity of the labeled products was determi

115 High radiochemical purity of the target compound is also achi

116 nation in 52-66% decay-corrected yields with radiochemical purity over 99%.

117 e (18)F-SO3F(-) was simple and afforded high radiochemical purity suitable for biologic evaluation (r

118 , (18)F-AlF-PSMA-11 was not stable in water (radiochemical purity was 64.5% immediately after purific

119 The radiolabeling efficiency was 80%-85%, radiochemical purity was 78%-89%, and specific activity

120 A high radiochemical purity was achieved without an incubation

121 Radiochemical purity was assessed by high-performance li

122 of 56% +/- 8% (non-decay-corrected), and the radiochemical purity was greater than 95%.

123 specific activity was 15-170 GBq/mumol, and radiochemical purity was greater than 97% (end of synthe

124 l yield was 1.40% +/- 0.16% (n = 4), and the radiochemical purity was greater than 98%.

125 /- 2 GBq/mumol (0.19 +/- 0.05 Ci/mumol), and radiochemical purity was greater than 99%.

126 The radiochemical purity was greater than 99%.

127 (18)F-l-FEHTP specific activity and radiochemical purity were 50-150 GBq/mumol and greater t

128 ochemical yield, 5% at the end of synthesis; radiochemical purity, >95%).

129 < 20 min (radiochemical yields, 58% +/- 9%; radiochemical purity, >97%) with molar activities of 12-

130 %-45%; specific activity, 650-870 GBq/mumol; radiochemical purity, >99%).

131 radiochemical yield (decay corrected), high radiochemical purity, and >90 GBq/mumol specific radioac

132 ith a PET nuclide at high specific activity, radiochemical purity, and yield.

133 ant quality standards with respect to yield, radiochemical purity, protein integrity, antigen binding

134 ontrol requirements for human use (including radiochemical purity, residual solvents, Kryptofix, chem

135 Radiochemical purity, stability up to 260 min, and bindi

136 After testing for radiochemical purity, three anesthetized Dutch-belted ra

137 % radiochemical yields with greater than 98% radiochemical purity.

138 he aqueous beam stop was recovered with >99% radiochemical purity.

139 mumol specific activity and greater than 95% radiochemical purity.

140 cted radiochemical yields with more than 99% radiochemical purity.

141 yield, respectively, and in greater than 99% radiochemical purity.

142 an average yield of 12% and greater than 99% radiochemical purity.

143 probe was synthesized with greater than 98% radiochemical purity.

144 ge of 5-10% radiochemical yield and over 95% radiochemical purity.

145 s only 25 min to prepare and results in >99% radiochemical purity.

146 (11)C-EKAP was prepared in good radiochemical purity.

147 end of synthesis (n = 17), and more than 99% radiochemical purity.

148 The rapid radiochemical reaction time (</=1 min) and high function

149 Additionally, the method results in high radiochemical recoveries and when compared to other dige

150 provides a self-diagnostic parameter for the radiochemical separation and overall instrument function

151 The proposed radiochemical separation can be completed within 2days f

152 A radiochemical separation procedure was developed to isol

153 e complete process of the sample collection, radiochemical separation, and measurement procedure spec

154 Protease cleavage and radiochemical sequencing identified receptor residue Leu

155 Radiochemical sequencing identified receptor residue Tyr

156 rification, proteolytic peptide mapping, and radiochemical sequencing of labeled wild-type and mutant

157 by this probe was identified as Glu(133) by radiochemical sequencing.

158 ars, and the current trend suggests that the radiochemical space available for PET applications will

159 ese medicinally important motifs expands the radiochemical space available for PET applications.

160 ed faster blood clearance in mice and better radiochemical stability compared to (99m)Tc-AGA-1.

161 Radiochemical stability of (99m)Tc-RYM1 was evaluated by

162 Radiochemical stability was studied in human serum, and

163 the neuroprotective effects of FLASH, while radiochemical studies confirmed that FLASH produced lowe

164 In vitro radiochemical sugar incorporation assays using these pur

165 We developed an efficient radiochemical synthesis for both 7alpha-18F-FM-DHT and 7

166 p decay and its ramifications (including the radiochemical synthesis of one organometallic compound),

167 cific activity, higher affinity, and simpler radiochemical synthesis than (18)F-BF4(-) METHODS: The a

168 cific activity, higher affinity, and simpler radiochemical synthesis than (18)F-BF4(-) The ability of

169 Methods: The radiochemical synthesis, cell uptake, cell kill, and bio

170 PTK7, was labeled with (18)F using a 2-step radiochemical synthesis, which featured a direct 1-step

171 e antigen (rhPSMA) ligands are applicable as radiochemical twins for both diagnostic PET imaging and

172 lts: (18)F-CDKi was obtained with an overall radiochemical uncorrected yield of 15% and radiochemical

173 (89)Zr-DFO-J591 was produced in high radiochemical yield (>77%) and purity (>99%), with a spe

174 Zr, scVR1/Zr, and scVR2/Zr tracers with high radiochemical yield (>87%), high specific activity (>/=9

175 ively] were radiofluorinated at a reasonable radiochemical yield (13%-18%) by use of site-specific ox

176 or), and provides [(18)F]FDOPA in reasonable radiochemical yield (2.44 +/- 0.70 GBq, 66 +/- 19 mCi, 5

177 iomers of [(18)F]FAMPe were obtained in good radiochemical yield (24-52% n = 8) and high radiochemica

178 cursor, (18)F-LY2459989 was prepared at high radiochemical yield (36% +/- 7% [mean +/- SD]), radioche

179 [(64)Cu]3-7 were prepared in high radiochemical yield (60-90%) and purity (>95%).

180 traction chromatography to afford an overall radiochemical yield (92 +/- 2%) and apparent molar activ

181 (18)F-7 was obtained in up to 20% radiochemical yield (decay corrected), high radiochemica

182 (18)F-FHNP was obtained in 15%-40% radiochemical yield (decay-corrected), with a specific a

183 (18)F-FPA was synthesized in 44% overall radiochemical yield (decay-corrected).

184 -protected 5-O-mesylate precursors in 17-35% radiochemical yield (decay-corrected).

185 led peptide can be obtained with a 31 +/- 6% radiochemical yield (n = 4, decay-corrected from (18)F-f

186 han 15 min, with an isolated decay-corrected radiochemical yield (RCY) of 24.8%, a radiochemical puri

187 ried (18)F and purified via a C18 cartridge (radiochemical yield 49.8% +/- 5.9% within 20-25 min) wit

188 (radiochemical purity > 95%, decay-corrected radiochemical yield = 31.6%, specific activity >/= 48.5

189 resulting in a lower isolated yield than the radiochemical yield according to instant thin-layer chro

190 GMIB-Nanobody was produced in 50.4% +/- 3.6% radiochemical yield and exhibited a dissociation constan

191 d 7alpha-18F-FM-norT, producing them in good radiochemical yield and high specific activity.

192 (18)F-FNDP can be synthesized in suitable radiochemical yield and high specific radioactivity and

193 d a method for preparing [(18)F]11 in useful radiochemical yield and in high specific activity from [

194 through radiomethylation in a range of 5-10% radiochemical yield and over 95% radiochemical purity.

195 E) and (99m)Tc-PSMA-I&S in consistently high radiochemical yield and purity (>/=98%, n > 50 preparati

196 DOTA-MC1RL conjugate was synthesized in high radiochemical yield and purity and was tested in vitro f

197 Results: [(64)Cu]Cu-c[E(4)W(5)C] radiochemical yield and purity were more than 95% and mo

198 poration in high selectivity and efficiency (radiochemical yield and purity, specific activity, and r

199 mpounds (86)Y- 4: - 6: were obtained in high radiochemical yield and purity, with specific radioactiv

200 din-4 was labeled with 89Zr and 68Ga in high radiochemical yield and purity.

201 produce no-carrier-added products with high radiochemical yield and purity.

202 5)Ac-RPS-074 was labeled in greater than 98% radiochemical yield and showed high (>10% injected dose/

203 03)Pb-L1-(203)Pb-L5 were synthesized in high radiochemical yield and specific activity.

204 hod using isotopic exchange gives suboptimal radiochemical yield and specific activity.

205 All 5 tracers were produced with good radiochemical yield and specific activity.

206 yl)- N,N-diethylacetamide ((18)F-6b) in high radiochemical yield and specific activity.

207 n approach proved to be superior in terms of radiochemical yield and stability, as well as in vivo pe

208 The decay-corrected radiochemical yield for (18)F-FPRGD4 was about 15%, with

209 g of cm09 was achieved in a greater than 96% radiochemical yield for all terbium radioisotopes.

210 -aspergillitine is prepared in 10 % isolated radiochemical yield from the corresponding phenyl(asperg

211 (18)F-FBzBMS 5 was synthesized with 0.54% radiochemical yield in 130 min, with an average specific

212 uorobenzoyl)insulin ((18)F-4b) in 6% overall radiochemical yield in 240 min.

213 (11)C-BMS-5p 3 was synthesized with 1.5% radiochemical yield in 36 min, with an average specific

214 The radiochemical yield of (11)C-metformin was 15% +/- 3% (n

215 The radiochemical yield of (18)F-FB-IL2 after high-performan

216 ics and was radiofluorinated with an average radiochemical yield of 10.6 +/- 3.8% (n = 16) and molar

217 [(18)F]3 was obtained in an average radiochemical yield of 11 +/- 4% and molar activities be

218 -trastuzumab-ThioFab) in 82 min with a total radiochemical yield of 13 +/- 3% and a specific activity

219 th radiochemical purity of more than 95% and radiochemical yield of 13.1% +/- 4.7% and 2.4% +/- 1.6%

220 nstant, 1.73 nM) was prepared in 1 step in a radiochemical yield of 14% +/- 7%, specific radioactivit

221 orobenzoate, with an overall decay-corrected radiochemical yield of 15% +/- 5% calculated from the st

222 ,5-b]pyrazine-3-carboxylate, with an overall radiochemical yield of 15-24%, a molar activity of 37-74

223 NOTA-ZPD-L1_1 was labeled, with a radiochemical yield of 15.1% +/- 5.6%, radiochemical pur

224 (18)F-PC-10 was synthesized with a radiochemical yield of 16% +/- 3% (decay-corrected).

225 corresponding tosylate precursor in a modest radiochemical yield of 2 +/- 0.6% with excellent radioch

226 nd radiochemical purity (>98%), satisfactory radiochemical yield of 20-35% (n > 20, non-decay correct

227 d conditions, (18)F-TFB was synthesized in a radiochemical yield of 20.0% +/- 0.7% (n = 3, uncorrecte

228 thesis process within 57 min with an overall radiochemical yield of 21%, decay-corrected.

229 omplished successfully with an incorporation radiochemical yield of 4%-12% (decay-corrected) from (18

230 precursor with (11)C-methyl iodide, giving a radiochemical yield of 51.7% +/- 4.7% (decay-corrected t

231 rification, (68)Ga-HZ220 was obtained with a radiochemical yield of 56% +/- 8% (non-decay-corrected),

232 abeled efficiently with (18)F in an isolated radiochemical yield of 62% +/- 2%, non-decay-corrected b

233 action purification with a decayed-corrected radiochemical yield of 63% +/- 5% (n = 5) and passed all

234 r to give formulated (89)Zr-DFO-AC-10 with a radiochemical yield of 80%, radiochemical purity greater

235 is time was 120 min, and the decay-corrected radiochemical yield of [(18)F]- 1 was about 25-30% ( n =

236 The radiochemical yield of [(18)F]3 was 16.4 +/- 4.8% (n = 4

237 Radiolabeling of cm09 was achieved with a radiochemical yield of greater than 96% at a specific ac

238 (47)Sc-cm10 was prepared with a radiochemical yield of more than 96% at a specific activ

239 led at a specific activity of 40 MBq/nmol, a radiochemical yield of more than 98%, and a stability of

240 adiosynthetic procedure in a decay-corrected radiochemical yield of up to 5% and molar radioactivitie

241 The radiochemical yield strongly depended on the iodonium co

242 dine ((123,125)I) was achieved in 55 +/- 12% radiochemical yield through a chelator-accelerated one-p

243 ion (t(1/2) = 109.7 min) in moderately high radiochemical yield to provide potential radioligands th

244 -MMR 3.49 sdAb was synthesized with a 5%-10% radiochemical yield using an automated and optimized pro

245 The decay-corrected radiochemical yield was 1.40% +/- 0.16% (n = 4), and the

246 The radiochemical yield was 13% +/- 3% (n = 7, decay-correct

247 The achieved radiochemical yield was 20 +/- 2% (n = 10, decay-correct

248 The radiochemical yield was 20%-25%.

249 sis time was 63 min, and the decay-corrected radiochemical yield was 36% +/- 3% (n = 8).

250 Radiochemical yield was 6%-35%, specific activity was 15

251 [(76)Br]5 was prepared in a 51% +/- 19% radiochemical yield with high radiochemical purity (>/=9

252 ic activities as high as 2.3 mCi/nmol (97.5% radiochemical yield) is presented.

253 ere synthesized within approximately 70 min (radiochemical yield, 35%-45%; specific activity, 650-870

254 lly pure l-[5-(11)C]-glutamine was obtained (radiochemical yield, 5% at the end of synthesis; radioch

255 igands succeeded after optimization efforts (radiochemical yield, approximately 20%-30% at the end of

256 The radiochemical yield, calculated from initial cyclotron-p

257 [(11)C]CPPC can be synthesized in sufficient radiochemical yield, purity, and specific radioactivity

258 Radiolabeling was accomplished with high radiochemical yield, purity, and specific radioactivity.

259 been prepared in 10 and 1.7% decay corrected radiochemical yield, respectively, and in greater than 9

260 t 79% +/- 13% (n = 6) and 94% +/- 6% (n = 6) radiochemical yield, respectively, with excellent radioc

261 i) of [(18)F]fluoride in 50 min (uncorrected radiochemical yield, specific activity of 815 +/- 185 GB

262 %) radiochemical purity and greater than 80% radiochemical yield.

263 d electrophilic iododestannylation in 60-90% radiochemical yield.

264 (18)F-SFB was produced with a 34%-38% radiochemical yield.

265 extremely small scale (20 nmol) with a high radiochemical yield.

266 ynthesis of tracers was accomplished in good radiochemical yields (15-39%), high specific activities

267 bioactive molecules and building blocks with radiochemical yields (RCY) ranging from 20% to 72% withi

268 r = Ph or 2-MeC(6)H(4), 85%) decay-corrected radiochemical yields (RCYs) of a single radioactive prod

269 of a variety of arenes and heteroarenes with radiochemical yields (RCYs, not decay-corrected) from 10

270 d radiofluorination was accomplished in good radiochemical yields and high molar activities.

271 (18)F]5 was synthesized in reproducibly high radiochemical yields and purity (>98%) as well as high s

272 iolabeling with (89)Zr was performed in high radiochemical yields and purity (>99%), and binding affi

273 as efficient and gave radioligands with high radiochemical yields and purity.

274 A comparison of radiochemical yields and reaction times for a microfluid

275 d lorlatinib is routinely prepared with good radiochemical yields and shows reasonable tumour uptake

276 thesized in 140 min with 24% and 10% overall radiochemical yields and specific activities of 10-127 G

277 d nanomolar affinities, were labeled in good radiochemical yields at high molar activities, and exhib

278 The non-decay-corrected radiochemical yields based on starting (18)F-fluoride us

279 ound 4-(11)C-MBZA was prepared in 46% +/- 7% radiochemical yields by reacting (11)C-methyltriflate wi

280 ound 4-(11)C-MBZA was prepared in 46% +/- 7% radiochemical yields by reacting (11)C-methyltriflate wi

281 precursor-based synthesis demonstrated high radiochemical yields in the large-scale production of ra

282 In the latter case, the radiochemical yields increased, and degradation of the 2

283 Results: Radiochemical yields of (89)Zr-DFO-N-suc-cetuximab and (

284 step procedure using a microwave system with radiochemical yields of 26.9 +/- 4.7%.

285 8F]SFB can be synthesized in decay-corrected radiochemical yields of 30%-35% and a specific radioacti

286 Fluorinated pH indicators were produced with radiochemical yields of 4%-11% at greater than 90% purit

287 taurine-conjugated bile acids proceeded with radiochemical yields of 61% (decay-corrected) or greater

288 7alpha-18F-FM-DHT and 7alpha-18F-FM-norT in radiochemical yields of about 30% and radiochemical puri

289 F]/F(-) and Kryptofix/K(2)CO(3) in DMSO with radiochemical yields of approximately 50-60% and specifi

290 t (67/68)Ga and (177)Lu labeling resulted in radiochemical yields of greater than 97% or greater than

291 ynthesized in 20% +/- 5% (n = 3) uncorrected radiochemical yields relative to (18)F-fluoride, with sp

292 Radiochemical yields were approximately 10-fold higher,

293 (89)Zr-ACKR3-mAb was produced in 80% +/- 5% radiochemical yields with greater than 98% radiochemical

294 obtained in greater than 50% decay-corrected radiochemical yields with more than 99% radiochemical pu

295 MA-5 to -10 by IE was completed in < 20 min (radiochemical yields, 58% +/- 9%; radiochemical purity,

296 roblematic due to long synthesis times, poor radiochemical yields, and low specific activities.

297 obtained in 16.3%-36.8% non-decay-corrected radiochemical yields, with 40-207 GBq/mumol specific act

298 nced Cu-mediated radiofluorination in 30-53% radiochemical yields.

299 corrected), and 59-75% (nondecay-corrected) radiochemical yields.

300 accomplished in 42% +/- 9% (decay-corrected) radiochemical yields.